• Novartis to Divest Sandoz US Dermatology Business to Aurobindo americanpharmaceuticalreview
    September 07, 2018
    Novartis has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, to Aurobindo Pharma USA, for $0.9 billion of cash plus $0.1 billion of ...
PharmaSources Customer Service